Aktienanalyse wird geladen …
GSK.L · LSE · Drug Manufacturers - General · Großbritannien
Kursverlauf von TradingView — beim Laden wird deine IP-Adresse an TradingView in den USA übertragen.
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 |
|---|
| 32,67 Mrd. |
| 5,72 Mrd. |
| 1,39 £ |
| 4,05 Mrd. |
| 19,9 Mio · 0,5 % |
| 45,9 Mio · 1,1 % |
| 72,4 % |
| 17,5 % |
| 1,17 £ |
| 0,09 £ |
| 0,64 £ |
| 2024 | 31,38 Mrd. | 2,58 Mrd. | 0,62 £ | 4,08 Mrd. | 18,3 Mio · 0,4 % | — | 71,2 % | 8,2 % | 0,88 £ | 0,08 £ | 0,61 £ |
|---|
| 2023 | 30,33 Mrd. | 4,93 Mrd. | 1,20 £ | 4,05 Mrd. | 16,3 Mio · 0,4 % | — | 71,8 % | 16,3 % | 1,09 £ | 0,08 £ | 0,56 £ |
|---|
| 2022 | 29,32 Mrd. | 14,96 Mrd. | 3,66 £ | 4,03 Mrd. | 18,4 Mio · 0,5 % | — | 67,4 % | 51 % | 1,28 £ | 0,09 £ | 0,88 £ |
|---|
| 2021 | 24,7 Mrd. | 4,39 Mrd. | 1,08 £ | 4 Mrd. | 18,3 Mio · 0,5 % | — | 67 % | 17,8 % | 1,32 £ | 0,09 £ | 1,25 £ |
|---|
| 2020 | 24,35 Mrd. | 5,75 Mrd. | 1,43 £ | 3,98 Mrd. | 17,9 Mio · 0,5 % | — | 67,4 % | 23,6 % | 1,63 £ | 0,08 £ | 0,95 £ |
|---|
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Bruttomarge | Nettomarge | FCF / Aktie |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 8,41 Mrd. | 435 Mio. | 0,11 £ | 4,06 Mrd. | 73,1 % | 5,2 % | 0,50 £ |
| Q1 2026 | 7,63 Mrd. | 1,74 Mrd. | 0,43 £ | 4,07 Mrd. | 75,4 % | 22,8 % | 0,17 £ |
| Q4 2025 | 8,62 Mrd. | 636 Mio. | 0,16 £ | 4,09 Mrd. | 69,2 % | 7,4 % | 0,31 £ |
| Q3 2025 | 8,55 Mrd. | 2,01 Mrd. | 0,49 £ | — | 73,6 % | 23,6 % | 0,33 £ |
| Q2 2025 | 7,99 Mrd. | 1,44 Mrd. | 0,35 £ | 4,11 Mrd. | 72,9 % | 18,1 % | 0,36 £ |
| Q1 2025 | 7,52 Mrd. | 1,62 Mrd. | 0,39 £ | 4,14 Mrd. | 74,2 % | 21,6 % | 0,17 £ |
GSK plc is a British multinational pharmaceutical and biotechnology company headquartered in London, England. The company focuses on discovering, developing, and manufacturing prescription medicines and vaccines for a wide range of diseases. GSK plc operates as a focused biopharma business, with research and development centred on four core therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. Its portfolio includes specialty medicines for complex conditions, vaccines used in national immunisation programmes, and general medicines addressing common chronic and acute illnesses. GSK plc serves healthcare systems, hospitals, and pharmacies worldwide, working closely with governments and global health organisations. As one of the larger global players in pharmaceuticals and vaccines, it plays a significant role in areas such as respiratory health, antiviral treatments, and prevention of infectious diseases through vaccination. Founded in 1999 and publicly listed in the United Kingdom, GSK plc today is a key constituent of the global healthcare and life sciences sector.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest GSK.L und jede andere Aktie unbegrenzt.